Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Bennett

Urogynecology and Reconstructive Pelvic Surgery Grand Rapids, MI Medical Doctor

NPI 1295757631 CMS profile 239563

5060 Cascade Rd Se Ste C-1, Grand Rapids, MI 49546

Open in the dashboard

General payments

$67,891

201 records reported · program years 2019–2025

Research payments

$4,274

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,812 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jason Bennett of Grand Rapids, MI is reported in the CMS Open Payments database as having received $67,891 across 201 general payments and $4,274 in research payments paid to them. Separately, studies naming them as principal investigator received $33,812 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,486 30
2024 General $13,066 40
2023 General $21,846 42
2022 General $10,491 47
2022 Research $2,200 3
2021 General $531 6
2020 General $9,965 11
2020 Research $2,074 3
2019 General $506 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Bennett
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Jason Bennett were reported at $11,486. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Jason Bennett Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $506 $358 $132–$1,270 $163
2020 $9,965 $198 $86–$642 $114
2021 $531 $361 $118–$1,182 $132
2022 $10,491 $410 $128–$1,175 $149
2023 $21,846 $434 $152–$1,344 $160
2024 $13,066 $494 $193–$1,331 $164
2025 $11,486 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $60,179 62 payments
  2. Medtronic USA, Inc. $2,328 6 payments
  3. Axonics Modulation Technologies, Inc. $1,540 18 payments
  4. Medtronic, Inc. $1,091 39 payments
  5. Memic Innovative Surgery Inc. $812 3 payments
  6. AbbVie, Inc. $431 20 payments
  7. Medical Device Business Services, Inc. $287 5 payments
  8. Coloplast Corp $200 8 payments
  9. Astellas Pharma US Inc $166 8 payments
  10. Intuitive Surgical, Inc. $127 2 payments
  11. Other $728 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $33,550 14 payments
  2. Travel and Lodging $11,272 42 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $9,800 4 payments
  4. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $7,500 2 payments
  5. Food and Beverage $3,449 134 payments
  6. Consulting Fee $2,170 1 payment
  7. Gift $127 2 payments
  8. Education $23 2 payments
Products named General payments · program years 2019–2025
  1. (1658) Clinical Educ Ultrasound $27,677 20 payments
  2. (1658) Educ Ultrasound $13,123 26 payments
  3. Clinical Educ Ultrasound $10,986 9 payments
  4. Educ Ultrasound $7,500 2 payments
  5. Axonics $1,310 11 payments
  6. (1658) Clin Educ US $894 5 payments
  7. Anovo Surgical System $812 3 payments
  8. INTERSTIM $669 37 payments
  9. Bulkamid $239 8 payments
  10. BOTOX $198 9 payments
  11. Other $1,749 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Cook Research Incorporated $2,178 5 payments
  2. Medtronic, Inc. $2,096 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

932

Median for Obstetrics & Gynecology: 65

Drug cost

$102,126

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

47.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 76 $55,414
Gemtesa Vibegron Brand 18 $17,560
Estradiol Generic 94 $10,296
Trospium Chloride Er Trospium Chloride Brand 50 $9,160
Trospium Chloride Generic 46 $2,301
Yuvafem Estradiol Brand 11 $1,856
Methenamine Hippurate Generic 11 $1,654
Nystatin Generic 70 $768
Metronidazole Generic 23 $710
Solifenacin Succinate Generic 11 $573

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$76,665

Medicare's payments for the services billed

Medicare patients

153

Average age 72

Services billed

2,065

153 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 62%
High blood pressure 58%
Osteoporosis 35%
Depression 34%
Diabetes 26%
Ischemic heart disease 19%
Chronic kidney disease 18%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $84
$84 — —
Veozah
  • Astellas Pharma US Inc $29
$29 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $20
$20 18 —
MYRBETRIQ
  • Astellas Pharma US Inc $19
$19 76 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record